公开(公告)号：US20220387614A1

公开(公告)日：2022-12-08

申请号：US17773637

申请日：2020-11-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Roberto ADAMO ,  Giuseppe DEL GIUDICE ,  Sanjay PHOGAT

IPC: A61K47/64 ,  A61K39/112 ,  A61K39/09

Abstract: The present invention provides a glycoconjugate for administration to a subject in a method comprising the steps of: (i) administering a first dose of glycoconjugate; (ii) subsequently administering a second dose of glycoconjugate; wherein the amount of glycoconjugate in the first dose or first and second doses are atypically low, and also related aspects.

公开(公告)号：US20220323354A1

公开(公告)日：2022-10-13

申请号：US17848294

申请日：2022-06-23

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: A61K9/127 ,  A61K39/12 ,  C12N15/86 ,  A61K31/7088 ,  A61K39/00

Abstract: Vaccines for eliciting an immune response are provided. The vaccines include lipid nanoparticles comprising lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These lipid nanoparticles can have essentially neutral surface charge at physiological pH and are effective for immunization.

公开(公告)号：US20220305120A1

公开(公告)日：2022-09-29

申请号：US17618283

申请日：2020-06-09

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Simona GALLORINI ,  Federico NAPOLITANO ,  Alessandra VITELLI

IPC: A61K39/39 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  A61P31/14

Abstract: Simian adenoviral vectors are formulated with bioadhesives and excipients that maintain immunogenicity. They can be administered mucosally to provide effective prophylaxis and therapy.

公开(公告)号：US20220288190A1

公开(公告)日：2022-09-15

申请号：US17632270

申请日：2020-08-03

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Pierre SAE HOUER ,  Pedro SANTANA DOS SANTOS ,  Laurent Bernard Jean STRODIOT ,  Bram VUYLSTEKE ,  Arnaud ZULIANI

IPC: A61K39/145 ,  A61K47/26 ,  A61K47/10 ,  A61K39/07 ,  A61K39/104 ,  A61K47/02

Abstract: The present invention relates to a process for preparing immunogenic compositions. More particularly, it relates to a process for preparing liquid compositions of Protein D polypeptide and their use in preparing immunogenic compositions comprising Protein D polypeptide which may be used in the treatment or prevention of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a subject, e.g. human.

公开(公告)号：US20220275397A1

公开(公告)日：2022-09-01

申请号：US17742221

申请日：2022-05-11

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefania CAPONE ,  Stefano COLLOCA ,  Antonella FOLGORI ,  Rossella MERONE

IPC: C12N15/86 ,  A61K39/21 ,  C07K14/005 ,  A61K39/12 ,  A61P31/18 ,  A61P31/14

Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

公开(公告)号：US20220257751A1

公开(公告)日：2022-08-18

申请号：US17628667

申请日：2020-07-21

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Massimilliano BIAGINI ,  Lucia Eleonora FONTANA ,  Anna GALEA ,  Nathalie NORAIS ,  Maria SCARSELLI

IPC: A61K39/385 ,  C07K14/205 ,  C07K14/21 ,  C07K14/22 ,  C07K14/245 ,  C07K14/31 ,  C07K14/33 ,  C12P21/00 ,  C12Q1/37 ,  G01N33/68

Abstract: The present invention provides analytical tools for the characterisation of bioconjugates, in particular for the measurement of glycosylation levels, and methods for absolute quantification of glycosylation sequences, as well as sequences and glycosylation sites for use in such methods.

公开(公告)号：US11414679B2

公开(公告)日：2022-08-16

申请号：US16466683

申请日：2017-12-07

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia Ammendola ,  Stefania Capone ,  Stefano Colloca ,  Antonella Folgori ,  Rossella Merone

IPC: C12N15/86 ,  C07K14/005 ,  A61K39/21 ,  A61K39/12 ,  A61P31/18 ,  A61P31/14 ,  A61K39/00

Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

公开(公告)号：US20220235095A1

公开(公告)日：2022-07-28

申请号：US17615254

申请日：2020-06-03

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Carine Berthe Ghislaine DE KESEL ,  Chad Austin FARRENBURG ,  Jeri Kay SANDVICK ,  Jeb Yeatts VANDENBURG

IPC: C07J63/00

Abstract: Saponin extracts containing at least 88% QS-21 main peak and >3% to 10% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.

公开(公告)号：US20220221455A1

公开(公告)日：2022-07-14

申请号：US17604008

申请日：2020-04-16

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Nathalie NORAIS ,  Silvia ROSSI PACCANI ,  Simona RONDINI

IPC: G01N33/569

Abstract: The present invention relates to the field of antigen binding proteins and the use of such antigen binding proteins in an assay. More particularly, it relates to antigen binding proteins which bind to an epitope of Protein E and antigen binding proteins which bind to an epitope of PilA. The present invention also relates to assays (particularly in vitro assays) for assessing binding to Protein E and/or PilA and the potency of vaccines containing Protein E and/or PilA. In particular the invention relates to in vitro relative potency assays used in the release of a vaccine to the public.

公开(公告)号：US20220204566A1

公开(公告)日：2022-06-30

申请号：US17565796

申请日：2021-12-30

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefano COLLOCA ,  Virginia AMMENDOLA ,  Fabiana GRAZIOLI ,  Alessandra Franz VITELLI ,  Alfredo NICOSIA ,  Riccardo CORTESE

IPC: C07K14/005 ,  C12N15/86 ,  C07K14/075 ,  C07K14/75 ,  A61K39/12 ,  C12N15/861 ,  A61K39/155 ,  A61K39/21 ,  C12N7/00

Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.